U.S., Dec. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07296666) titled 'Adjuvant Chemotherapy for BTC Based on 3D-PTA' on Nov. 24.
Brief Summary: This is a prospective, open-label, controlled, multicenter clinical study designed to observe and evaluate the efficacy and safety of chemotherapy (including capecitabine monotherapy) guided by 3D-PTA drug sensitivity testing versus capecitabine monotherapy as adjuvant treatment in patients with stage II/III cholangiocarcinoma after surgery.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Cholangiocarcinoma
Intervention:
DRUG: Chemotherapy (preferably with a single chemotherapeutic agent) combined with capecitabine (including capecitab...